We propose that inhibition of SREBP-controlled HMG-CoA reductase activation represent an important statin-mediated mechanism of the improvement of dyslipidemia induced by SGAs, and the hypolipidemic effect of statin might be partly via activating the function of BAT. This evidence concerns the gene HMGCR and metabolic syndrome.